What this page establishes
- The ADA Standards of Care state that when adding a GLP-1 RA or a dual GIP/GLP-1 RA, sulfonylureas should be discontinued or reduced and insulin adjusted to avoid hypoglycaemia, for example reducing bolus by 10 to 20% and basal by about 10% if HbA1c is under 7.5%.
- The ADA advises reassessing the need for and dose of higher-hypoglycaemia-risk medications (sulfonylureas, meglitinides, insulin) whenever a new glucose-lowering agent is started.
- GLP-1 RAs and tirzepatide carry a lower intrinsic hypoglycaemia risk than insulin or sulfonylureas because their insulinotropic effect is glucose-dependent.
- In FLOW (3,533 adults with type 2 diabetes and chronic kidney disease), semaglutide 1.0 mg reduced major kidney events by 24%, major cardiovascular events by 18% and all-cause death by 20% versus placebo.
Quick answers
I do not have diabetes. Can this still give me a hypo?
Rarely on its own, because the insulin-stimulating effect is glucose-dependent and switches off as glucose falls toward normal.
Read the full answer
The risk that matters is combination: insulin and sulfonylureas have no such switch, and lows become a serious prospect when a GLP-1 is added on top of either. If you take neither, the hypoglycaemia conversation on this page is largely not about you.I am on metformin only. Does anything need adjusting?
The medications the ADA guidance names for reassessment are sulfonylureas, meglitinides and insulin, which are the ones that lower glucose regardless of what glucose is doing.
Read the full answer
Metformin is not in that group. Whether your own regimen needs changing is still a call for whoever can see your HbA1c and the rest of what you take.My prescriber added a GLP-1 and did not change my sulfonylurea. Should I?
Do not change it yourself. The ADA Standards of Care 2026 say sulfonylureas should be discontinued or reduced when a GLP-1 RA is added, so it is a reasonable and specific question to put to your prescriber promptly.
Read the full answer
Quote the guidance if it helps. The dose decision is theirs.
Start with the item that can cause harm today. A GLP-1 on its own rarely pushes blood glucose below normal, because its effect on insulin secretion is glucose-dependent and switches off as glucose falls toward normal. Insulin and sulfonylureas have no such switch. Adding a GLP-1 on top of either produces genuine hypoglycaemia risk, and the ADA Standards of Care 2026 say plainly that sulfonylureas should be discontinued or reduced and insulin adjusted at the point the GLP-1 is added. If you take insulin or a sulfonylurea and nobody has revisited those doses, that is the phone call to make. Everything else on this page is context.
Same molecule, two indications
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. What differs between the pairs is the indication they are approved for and the dose ceiling that goes with it, not the drug in the pen.
That is why the same active ingredient can carry different maximum doses, different titration schedules and different sets of trial evidence attached to its name. The ADA Standards of Care reflect the same split, handling obesity pharmacotherapy in a separate chapter from glycaemic treatment, because the two indications have different targets and different dose ranges.
For a patient this matters mostly in which trials apply to you, what dose you can reach, and what your insurer is willing to fund. It does not mean one brand is a stronger or weaker version of the other molecule.
The dose ceiling is the part with real clinical consequence. Weight-management dosing runs higher than diabetes dosing for both molecules, and the trials people quote were run at specific doses. A number produced at one dose does not transfer to a different one just because the pen contains the same drug.
| Molecule | Type 2 diabetes brand | Weight management brand | Headline outcome trial |
|---|---|---|---|
| Semaglutide | Ozempic | Wegovy | SELECT (obesity indication, 2.4 mg, no diabetes): 20% MACE reduction. FLOW (T2D with CKD, 1.0 mg): 24% reduction in major kidney events |
| Tirzepatide | Mounjaro | Zepbound | SURMOUNT-1 (weight loss). Zepbound also carries a US indication for moderate-to-severe obstructive sleep apnoea in adults with obesity |
Hypoglycaemia: why the drug alone rarely causes it
GLP-1 receptor agonists increase insulin secretion and suppress glucagon in a glucose-dependent way. As blood glucose falls toward normal, the insulinotropic drive falls with it. That built-in brake is why the class carries a lower intrinsic hypoglycaemia risk than insulin or sulfonylureas.
Sulfonylureas force insulin release regardless of what glucose is doing. Injected insulin acts regardless of what glucose is doing. Put either underneath a GLP-1 and the brake is gone, because the glucose-lowering that keeps arriving is not the glucose-dependent kind.
Slowed gastric emptying adds a second, quieter problem. It changes when carbohydrate from a meal reaches the bloodstream, so a mealtime insulin dose timed for the old absorption curve can peak before the glucose it was matched to arrives. On a CGM trace that shows up as a post-meal dip followed by a later rise, and it is a pattern worth taking to your diabetes team rather than solving alone.
What the ADA Standards of Care actually say
The 2026 Standards of Care are specific rather than general on this. When adding a GLP-1 RA or a dual GIP/GLP-1 RA, sulfonylureas should be discontinued or reduced, and insulin should be adjusted. The worked example given is reducing bolus insulin by 10 to 20% and basal by about 10% if HbA1c is under 7.5%.
The guidance goes wider than that single moment. The ADA advises reassessing the need for and the dose of any higher-hypoglycaemia-risk medication, meaning sulfonylureas, meglitinides and insulin, whenever a new glucose-lowering agent is started.
Those percentages are printed here because knowing they exist helps you ask the right question. They are not a self-adjustment recipe. The person who sets your actual numbers is the person who can see your HbA1c, your CGM data and the rest of your regimen.
Kidney outcomes: FLOW is a diabetes trial
FLOW enrolled 3,533 adults with type 2 diabetes and chronic kidney disease. Semaglutide 1.0 mg reduced major kidney events by 24%, major cardiovascular events by 18% and all-cause death by 20% against placebo.
That is a strong result and it is tightly scoped. It applies to type 2 diabetes with chronic kidney disease, at the 1.0 mg semaglutide dose. It is not a general claim that GLP-1s protect kidneys in people without diabetes at obesity doses.
The other half of the kidney story has to sit next to it. FDA labelling across the class warns of serious kidney injury following dehydration, in some cases requiring haemodialysis, with most reported cases following nausea, vomiting or diarrhoea. Both facts are true simultaneously, and publishing either one alone gives a misleading impression in opposite directions.
Cardiovascular outcomes: SELECT is not a diabetes trial
The 20% MACE reduction that gets quoted everywhere came from SELECT, which enrolled adults with overweight or obesity and established cardiovascular disease and specifically without diabetes.
That makes it the evidence base for the obesity indication, not the diabetes one. The cardiovascular evidence in type 2 diabetes sits in separate trials with separate populations and separate numbers.
This distinction gets lost constantly, in both directions. People with diabetes assume SELECT applies to them, and people without diabetes assume the diabetes trials do. Neither transfer is safe, and the specific population a trial enrolled is usually the most informative line in any summary of it.
HbA1c, CGM patterns and what changes first
Glucose responds before weight does, which surprises people who started the drug primarily to lose weight. The glucose-dependent insulin effect and the glucagon suppression are working from the first doses, while meaningful weight change takes months.
On a CGM the earliest visible change is usually to post-meal excursions, which flatten as gastric emptying slows and the glucose-dependent insulin response kicks in. Overnight and fasting values often follow.
The pattern worth flagging to your team is a new low, or a new post-meal dip, particularly if you are also on insulin. A CGM makes the desynchronised-insulin-timing problem visible in a way finger-sticks do not, which is a good reason to bring the traces to an appointment rather than describing them from memory.
Timing effects are also strongest at exactly the moments the label flags: after the first dose and after each escalation, when gastric emptying is most delayed. A CGM trace that behaved predictably at one dose can start misbehaving in the week after a step up, which is a reason to keep watching rather than to assume the regimen is settled.
Type 1 diabetes is a different conversation
GLP-1 receptor agonists are not indicated for type 1 diabetes. Any use in type 1 is off-label.
The reasoning is straightforward: the class works substantially by modulating an endogenous insulin response that type 1 diabetes has largely destroyed, and the remaining effects arrive in a person entirely dependent on injected insulin, where hypoglycaemia risk and ketoacidosis risk both need managing on a different footing.
None of that means it is never done. It means it is a specialist decision made with a full picture of one person's physiology, and general educational content is the wrong place to reason about it.
Sick days, GI upset and glucose control
A vomiting-and-diarrhoea illness is harder to manage on a GLP-1 plus insulin than on either alone. Food is not staying down, absorption is unpredictable, dehydration is accumulating, and the labelled acute kidney injury pathway runs directly through that combination.
Most diabetes services have sick-day rules covering what to do about specific medications when you cannot eat or keep fluids down. If yours has not given you those, asking for them is a reasonable thing to do at a routine appointment rather than during the illness itself.
Persistent vomiting or diarrhoea while on insulin is a contact-your-team situation rather than a wait-and-see one.
When to contact a clinician
The first two are the ones that route straight to your diabetes team. The last two need urgent assessment.
- Repeated or severe low blood glucose, especially overnight or after a missed meal
- Hypoglycaemia unawareness, meaning lows arriving without the usual warning symptoms
- Persistent vomiting or diarrhoea while on insulin, given the combination of dehydration risk and unpredictable glucose
- Severe abdominal pain radiating to the back, which can indicate pancreatitis and needs urgent assessment
- Rapidly worsening vision after a fast HbA1c drop, which raises a retinopathy progression concern
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| The ADA Standards of Care state that when adding a GLP-1 RA or a dual GIP/GLP-1 RA, sulfonylureas should be discontinued or reduced and insulin adjusted to avoid hypoglycaemia, for example reducing bolus by 10 to 20% and basal by about 10% if HbA1c is under 7.5%. | established | ADA Standards of Care in Diabetes 2026, Section 9: Pharmacologic Approaches to Glycemic Treatment |
| The ADA advises reassessing the need for and dose of higher-hypoglycaemia-risk medications (sulfonylureas, meglitinides, insulin) whenever a new glucose-lowering agent is started. | established | ADA Standards of Care 2026, Section 9 |
| GLP-1 RAs and tirzepatide carry a lower intrinsic hypoglycaemia risk than insulin or sulfonylureas because their insulinotropic effect is glucose-dependent. | established | ADA Standards of Care 2026, Section 9 |
| In FLOW (3,533 adults with type 2 diabetes and chronic kidney disease), semaglutide 1.0 mg reduced major kidney events by 24%, major cardiovascular events by 18% and all-cause death by 20% versus placebo. | established | FLOW trial analyses (PMC) |
| SELECT, the 20% MACE-reduction trial, enrolled adults with overweight or obesity and established cardiovascular disease WITHOUT diabetes, so it is the evidence base for the obesity indication rather than the diabetes one. | established | SELECT trial summary, ACC |
| The ADA's obesity and weight-management chapter addresses obesity pharmacotherapy separately from glycaemic treatment, reflecting that the two indications have different targets and dose ranges. | established | ADA Standards of Care in Diabetes 2026, Section 8 |
| FDA labelling now carries acute kidney injury warnings tied to dehydration from severe GI reactions across the GLP-1 class, which matters more when other glucose-lowering agents are on board. | established | OZEMPIC (semaglutide) US Prescribing Information, FDA |
| Tirzepatide: 2.5 mg initiation then 5 / 10 / 15 mg weekly maintenance; 16.0% / (10 mg intermediate) / 22.5% mean loss at 72 weeks (SURMOUNT-1). | established | Eli Lilly / NEJM |
Questions people ask
My vision blurred after my HbA1c dropped quickly. Is that the drug?
A fast fall in HbA1c raises a retinopathy progression concern, which is why rapidly worsening vision after one is on the urgent list rather than the next-appointment list. Nothing on this page can tell you which cause applies to your eyes. Get it assessed rather than waiting to see whether it settles.
Sources
- ADA Standards of Care in Diabetes 2026, Section 9: Pharmacologic Approaches to Glycemic Treatment
- FLOW trial analyses (PMC)
- SELECT trial summary, ACC
- ADA Standards of Care in Diabetes 2026, Section 8
- OZEMPIC (semaglutide) US Prescribing Information, FDA
- Eli Lilly / NEJM
Keep reading
- GLP-1 and Kidney Health: Protection, and the Dehydration WarningChronic protection and acute vulnerability at the same time. FLOW's benefit is specific to type 2 diabetes wit
- GLP-1 and Heart Rate: The Resting Increase and What SELECT ShowedThe heart-rate rise is real, labelled and small. The outcome trial found a 20% reduction in major cardiovascul
- GLP-1 and Sleep, Including Sleep ApnoeaSleep apnoea is the one sleep outcome with a trial and an approval behind it. Everything else here is much wea
- GLP-1 and GI Side Effects: Nausea, Constipation and RefluxGI effects are the dominant labelled adverse reactions, inseparable from how the drug works, and concentrated
- GLP-1 and Surgery: What to Tell Your AnaesthetistTell the anaesthetic team you are on this drug. Perioperative guidance changed materially in October 2024, and
- GLP-1 and Hydration: Why Fluid Intake Drops and Why It MattersA soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the docum